MA50629A - Composés monobactames de chromane pour le traitement d'infections bactériennes - Google Patents

Composés monobactames de chromane pour le traitement d'infections bactériennes

Info

Publication number: MA50629A
Authority: MA; Morocco
Prior art keywords: monobactam; treatment; bacterial infections; chroman compounds; chroman
Prior art date: 2017-10-02

Application number

MA050629A

Other languages

English (en)

Inventor

Tesfaye Biftu

Xianhai Huang

Weiguo Liu

Weidong Pan

Min Park

Alexander Pasternak

Wanying Sun

Haifeng Tang

Yi Zang

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-02

Filing date

2018-09-27

Publication date

2021-03-31

2018-09-27 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2021-03-31 Publication of MA50629A publication Critical patent/MA50629A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA050629A 2017-10-02 2018-09-27 Composés monobactames de chromane pour le traitement d'infections bactériennes MA50629A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762566779P	2017-10-02	2017-10-02

Publications (1)

Publication Number	Publication Date
MA50629A true MA50629A (fr)	2021-03-31

Family

ID=65994576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050629A MA50629A (fr)	2017-10-02	2018-09-27	Composés monobactames de chromane pour le traitement d'infections bactériennes

Country Status (27)

Country	Link
US (1)	US11433055B2 (fr)
EP (1)	EP3691639B1 (fr)
JP (1)	JP7252948B2 (fr)
KR (1)	KR102425959B1 (fr)
CN (2)	CN118496221A (fr)
AU (1)	AU2018345523B2 (fr)
BR (1)	BR112020006381A8 (fr)
CA (1)	CA3076022C (fr)
CL (1)	CL2020000860A1 (fr)
CO (1)	CO2020004087A2 (fr)
CR (1)	CR20200148A (fr)
DO (1)	DOP2020000058A (fr)
EA (1)	EA202090604A1 (fr)
ES (1)	ES2968467T3 (fr)
GE (1)	GEP20227406B (fr)
IL (1)	IL273306B (fr)
JO (1)	JOP20200130A1 (fr)
MA (1)	MA50629A (fr)
MX (1)	MX2020003581A (fr)
NI (1)	NI202000023A (fr)
PE (1)	PE20201256A1 (fr)
PH (1)	PH12020550107A1 (fr)
SA (1)	SA520411571B1 (fr)
SG (1)	SG11202002575UA (fr)
UA (1)	UA126000C2 (fr)
WO (1)	WO2019070492A1 (fr)
ZA (1)	ZA202001721B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110156697B (zh) *	2019-05-30	2022-05-06	常州沃腾化工科技有限公司	一种1,2-二甲基-1,4,5,6-四氢嘧啶的合成方法
WO2021257857A1 (fr)	2020-06-19	2021-12-23	Incyte Corporation	Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f
WO2021257863A1 (fr)	2020-06-19	2021-12-23	Incyte Corporation	Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
WO2022006456A1 (fr)	2020-07-02	2022-01-06	Incyte Corporation	Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2
AU2021300429A1 (en)	2020-07-02	2023-02-16	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022120048A1 (fr) *	2020-12-03	2022-06-09	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Inhibiteurs de hdac
US11919908B2 (en)	2020-12-21	2024-03-05	Incyte Corporation	Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
US11958861B2 (en)	2021-02-25	2024-04-16	Incyte Corporation	Spirocyclic lactams as JAK2 V617F inhibitors
AU2022391635A1 (en) *	2021-11-18	2024-05-16	Merck Sharp & Dohme Llc	Chromane amidine monobactam antibiotics
CN119173514A (zh)	2022-03-17	2024-12-20	因赛特公司	作为jak2 v617f抑制剂的三环脲化合物
WO2024019916A2 (fr) *	2022-07-18	2024-01-25	Merck Sharp & Dohme Llc	Composés monobactame amidine chromane pour le traitement d'infections bactériennes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4684722A (en)	1986-01-06	1987-08-04	E. R. Squibb & Sons, Inc.	Monosulfactams
US5250691A (en)	1991-09-09	1993-10-05	E. R. Squibb & Sons, Inc.	Heteroaryl derivatives of monocyclic beta-lactam antibiotics
CN102988362B (zh)	2005-12-07	2014-11-05	巴斯利尔药物股份公司	单环-内酰胺类抗生素与β-内酰胺酶抑制剂的有效的联合应用
EP1938822A1 (fr)	2006-12-21	2008-07-02	Novartis AG	Thérapie combinée pour le traitement des maladies des voies respiratoires
SG189174A1 (en)	2010-10-11	2013-05-31	Biogen Idec Internat Neuroscience Gmbh	Human anti-tau antibodies
JP5777725B2 (ja)	2010-11-29	2015-09-09	ファイザー・インク	モノバクタム
UY34585A (es)	2012-01-24	2013-09-02	Aicuris Gmbh & Co Kg	Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
SI2857039T1 (sl)	2012-05-31	2020-03-31	Osaka City University	Terapevtsko sredstvo ali profilaktično sredstvo za demenco
US20140275007A1 (en)	2013-03-14	2014-09-18	Rempex Pharmaceuticals, Inc.	Oxamazin antibiotics
WO2015103583A1 (fr)	2014-01-06	2015-07-09	President And Fellows Of Harvard College	Monobactames et procédés de synthèse et d'utilisation de ces derniers
UA121383C2 (uk)	2014-03-24	2020-05-25	Новартіс Аг	Органічні сполуки, що є монобактамами, для лікування бактеріальних інфекцій
TWI664190B (zh)	2014-06-27	2019-07-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗－ｔａｕ抗體
US9642831B2 (en)	2014-10-31	2017-05-09	Abbvie S.Á.R.L.	Substituted chromanes and method of use
FR3031423B1 (fr) *	2015-01-06	2018-11-30	Centre National De La Recherche Scientifique	Procede et dispositif de conversion de courant et vehicule comportant un tel dispositif
CA3008006C (fr)	2015-12-15	2024-04-09	Merck Sharp & Dohme Corp.	Composes de biarylmonobactame et procedes d'utilisation correspondants pour le traitement d'infections bacteriennes
KR102408800B1 (ko) *	2016-03-07	2022-06-13	머크 샤프 앤드 돔 코포레이션	비시클릭 아릴 모노박탐 화합물 및 박테리아 감염의 치료를 위한 그의 사용 방법

2018
- 2018-09-27 MA MA050629A patent/MA50629A/fr unknown
- 2018-09-27 JP JP2020518661A patent/JP7252948B2/ja active Active
- 2018-09-27 EA EA202090604A patent/EA202090604A1/ru unknown
- 2018-09-27 PE PE2020000692A patent/PE20201256A1/es unknown
- 2018-09-27 AU AU2018345523A patent/AU2018345523B2/en active Active
- 2018-09-27 WO PCT/US2018/053039 patent/WO2019070492A1/fr active Application Filing
- 2018-09-27 SG SG11202002575UA patent/SG11202002575UA/en unknown
- 2018-09-27 BR BR112020006381A patent/BR112020006381A8/pt unknown
- 2018-09-27 CR CR20200148A patent/CR20200148A/es unknown
- 2018-09-27 CN CN202410563311.2A patent/CN118496221A/zh active Pending
- 2018-09-27 ES ES18864229T patent/ES2968467T3/es active Active
- 2018-09-27 CN CN201880064269.2A patent/CN111201021B/zh active Active
- 2018-09-27 CA CA3076022A patent/CA3076022C/fr active Active
- 2018-09-27 UA UAA202002037A patent/UA126000C2/uk unknown
- 2018-09-27 MX MX2020003581A patent/MX2020003581A/es unknown
- 2018-09-27 EP EP18864229.2A patent/EP3691639B1/fr active Active
- 2018-09-27 JO JOP/2020/0130A patent/JOP20200130A1/ar unknown
- 2018-09-27 KR KR1020207012234A patent/KR102425959B1/ko active Active
- 2018-09-27 GE GEAP201815303A patent/GEP20227406B/en unknown
- 2018-09-27 US US16/651,456 patent/US11433055B2/en active Active
2020
- 2020-03-15 IL IL273306A patent/IL273306B/en unknown
- 2020-03-16 DO DO2020000058A patent/DOP2020000058A/es unknown
- 2020-03-18 ZA ZA2020/01721A patent/ZA202001721B/en unknown
- 2020-03-19 SA SA520411571A patent/SA520411571B1/ar unknown
- 2020-03-20 PH PH12020550107A patent/PH12020550107A1/en unknown
- 2020-03-24 NI NI202000023A patent/NI202000023A/es unknown
- 2020-03-31 CL CL2020000860A patent/CL2020000860A1/es unknown
- 2020-03-31 CO CONC2020/0004087A patent/CO2020004087A2/es unknown

Also Published As

Publication number	Publication date
CA3076022A1 (fr)	2019-04-11
NZ762899A (en)	2024-07-26
JP2020536082A (ja)	2020-12-10
KR102425959B1 (ko)	2022-07-27
IL273306A (en)	2020-04-30
SG11202002575UA (en)	2020-04-29
ES2968467T3 (es)	2024-05-09
UA126000C2 (uk)	2022-07-27
AU2018345523B2 (en)	2021-10-21
AU2018345523A1 (en)	2020-03-26
US20200297702A1 (en)	2020-09-24
JP7252948B2 (ja)	2023-04-05
BR112020006381A2 (pt)	2020-09-24
EA202090604A1 (ru)	2020-10-15
IL273306B (en)	2022-04-01
CN118496221A (zh)	2024-08-16
BR112020006381A8 (pt)	2023-04-11
GEP20227406B (en)	2022-08-25
CO2020004087A2 (es)	2020-04-24
WO2019070492A1 (fr)	2019-04-11
PE20201256A1 (es)	2020-11-16
KR20200058520A (ko)	2020-05-27
CL2020000860A1 (es)	2020-08-14
CN111201021A (zh)	2020-05-26
JOP20200130A1 (ar)	2020-05-28
CA3076022C (fr)	2023-01-17
EP3691639A1 (fr)	2020-08-12
SA520411571B1 (ar)	2024-08-27
EP3691639B1 (fr)	2023-11-15
EP3691639A4 (fr)	2021-03-31
ZA202001721B (en)	2023-02-22
US11433055B2 (en)	2022-09-06
CN111201021B (zh)	2024-08-23
DOP2020000058A (es)	2020-09-15
PH12020550107A1 (en)	2020-12-07
CR20200148A (es)	2020-05-22
MX2020003581A (es)	2020-07-22
NI202000023A (es)	2020-09-24

Publication	Publication Date	Title
MA50629A (fr)	2021-03-31	Composés monobactames de chromane pour le traitement d'infections bactériennes
MA44083A (fr)	2021-06-02	Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3728271A4 (fr)	2021-06-23	Composés macrocycliques pour le traitement de maladie
MA45539A (fr)	2019-05-08	Dihydropyranopyrimidines pour le traitement d'infections virales
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
EP3374350A4 (fr)	2019-10-02	Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
EP3634417C0 (fr)	2023-07-12	Dérivés quinazoline-pyrazole pour le traitement de troubles liés au cancer
EP3541408A4 (fr)	2020-06-24	Compositions et méthodes pour le traitement de l'angiogenèse aberrante
EP3013345A4 (fr)	2016-11-30	Composés pour le traitement d'une amyotrophie spinale
MA43811A (fr)	2018-11-28	Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
EP3405183A4 (fr)	2019-12-11	Dérivés d'adamatane pour le traitement d'une infection à filovirus
EP3288592A4 (fr)	2019-01-09	Utilisation de cannabidiol pour le traitement de spasmes infantiles
EP3440493A4 (fr)	2019-05-22	Traitement d'échantillon pour microscopie
EP3285776A4 (fr)	2019-01-23	Méthodes de traitement d'infections bactériennes
EP3374355A4 (fr)	2019-04-17	Composés à base de pyrone pour traiter les infections bactériennes
EP3766497A4 (fr)	2021-12-08	Médicament pour le traitement de la toux
MA45845A (fr)	2019-06-12	Traitement d'association pour cancers hématologiques
EP3740246C0 (fr)	2023-06-07	Perturbation du complexe linc pour le traitement de laminopathies
MA49576A (fr)	2021-04-07	Compositions et méthodes pour le traitement d'infections fongiques
MA51738A (fr)	2021-05-12	Composés pour le traitement de la douleur
EP3430400A4 (fr)	2019-10-30	Schémas posologiques pour le traitement d'infections fongiques
EP3541379A4 (fr)	2020-05-27	Compositions pour le traitement de l'hypertension
MA55218A (fr)	2022-01-12	Eskétamine pour le traitement de la dépression
EP3344650A4 (fr)	2019-04-17	Aav-epo pour le traitement d'animaux de compagnie
MA45552A (fr)	2019-05-08	Compositions destinées au traitement de l'amylose